"Final data from phase 2a study underscores potential for fostrox + Lenvima to become first approved option in second-line liver cancer" Financial summary for the quarterNet turnover amounted ...

DÜSSELDORF, GERMANY, ATLANTA, GA, AND NEW YORK, NY / ACCESS Newswire / April 28, 2025 / As previously disclosed, and pursuant to the terms and conditions set forth in the Share Purchase Agreement, dat ...